BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16376072)

  • 1. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data.
    Polyzos NP; Pavlidis N; Paraskevaidis E; Ioannidis JP
    Eur J Cancer; 2006 Feb; 42(3):319-26. PubMed ID: 16376072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy in endometrial cancer.
    Obel JC; Friberg G; Fleming GF
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):459-68. PubMed ID: 16981669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy in metastatic or recurrent endometrial carcinoma].
    Deppe G; Baumann P; Munkarah A
    Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
    Hogberg T
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.
    Golfinopoulos V; Pentheroudakis G; Salanti G; Nearchou AD; Ioannidis JP; Pavlidis N
    Cancer Treat Rev; 2009 Nov; 35(7):570-3. PubMed ID: 19539430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormonal therapy and chemotherapy of endometrial cancer].
    Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
    Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of endometrial cancer.
    Barrena Medel NI; Bansal S; Miller DS; Wright JD; Herzog TJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):1939-51. PubMed ID: 19586421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    McCulloch M; See C; Shu XJ; Broffman M; Kramer A; Fan WY; Gao J; Lieb W; Shieh K; Colford JM
    J Clin Oncol; 2006 Jan; 24(3):419-30. PubMed ID: 16421421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for high-risk early-stage endometrial cancer.
    Kodama J; Seki N; Hiramatsu Y
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):42-7. PubMed ID: 17218851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
    Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
    Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
    Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
    Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
    Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W; Hehr T; Budach V; Belka C; Dietz K
    BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.